The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned HC seeks Novo Nordisk's reply on Natco plea to revoke patent. The response from the Company is awaited.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Smallcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Natco Pharma to clarify a recent news item about the Delhi High Court seeking Novo Nordisk's reply on Natco's plea to revoke a patent. The company has not yet submitted its response to the exchange. The underlying patent dispute is still pending before the court. No ruling, order, or outcome has been reported at this stage.
This is a routine exchange query and does not indicate any adverse regulatory action against Natco. Investors should wait for the company's clarification and any court ruling before drawing conclusions; near-term stock movement may depend on how the patent plea progresses.